1. Home
  2. SCYX vs NVFY Comparison

SCYX vs NVFY Comparison

Compare SCYX & NVFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • NVFY
  • Stock Information
  • Founded
  • SCYX 1999
  • NVFY 2003
  • Country
  • SCYX United States
  • NVFY United States
  • Employees
  • SCYX N/A
  • NVFY N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • NVFY Home Furnishings
  • Sector
  • SCYX Health Care
  • NVFY Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • NVFY Nasdaq
  • Market Cap
  • SCYX 32.3M
  • NVFY 36.8M
  • IPO Year
  • SCYX 2014
  • NVFY N/A
  • Fundamental
  • Price
  • SCYX $0.79
  • NVFY $5.49
  • Analyst Decision
  • SCYX
  • NVFY
  • Analyst Count
  • SCYX 0
  • NVFY 0
  • Target Price
  • SCYX N/A
  • NVFY N/A
  • AVG Volume (30 Days)
  • SCYX 574.3K
  • NVFY 856.2K
  • Earning Date
  • SCYX 11-05-2025
  • NVFY 11-13-2025
  • Dividend Yield
  • SCYX N/A
  • NVFY N/A
  • EPS Growth
  • SCYX N/A
  • NVFY N/A
  • EPS
  • SCYX N/A
  • NVFY N/A
  • Revenue
  • SCYX $3,257,000.00
  • NVFY $9,813,990.00
  • Revenue This Year
  • SCYX $422.61
  • NVFY N/A
  • Revenue Next Year
  • SCYX $240.56
  • NVFY N/A
  • P/E Ratio
  • SCYX N/A
  • NVFY N/A
  • Revenue Growth
  • SCYX N/A
  • NVFY N/A
  • 52 Week Low
  • SCYX $0.66
  • NVFY $0.39
  • 52 Week High
  • SCYX $1.62
  • NVFY $5.93
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 36.53
  • NVFY 76.48
  • Support Level
  • SCYX $0.74
  • NVFY $5.30
  • Resistance Level
  • SCYX $1.14
  • NVFY $5.53
  • Average True Range (ATR)
  • SCYX 0.07
  • NVFY 0.25
  • MACD
  • SCYX -0.04
  • NVFY -0.08
  • Stochastic Oscillator
  • SCYX 11.22
  • NVFY 61.54

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NVFY Nova Lifestyle Inc.

Nova Lifestyle Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.

Share on Social Networks: